Transarterial chemoembolization (TACE) plus apatinib-combined therapy versus TACE alone in the treatment of intermediate to advanced hepatocellular carcinoma patients: A real-world study - 06/07/22
, Donghui Liu, Chu Wang, Shilong Yu, Gang Jin, Chun Wang, Beiguang Zhang, Dongxu Zhang, Dan ShaoHighlights |
• | The OS was prolonged in cTACE plus ACT group compared with cTACE group (P<0.001). |
• | cTACE plus ACT (vs. cTACE) independently related to longer OS (HR: 0.504, P = 0.001). |
• | No new adverse events were observed after treating cTACE plus ACT in HCC patients. |
• | No grade 4 adverse events and treatment-related death occurred. |
Abstracts |
Background |
Apatinib exhibits the synergistic effect with transarterial chemoembolization (TACE) though inhibiting the neoangiogenetic reaction caused by TACE. In this real-world study, we aimed to evaluate the efficacy and safety of TACE plus apatinib-combined therapy (ACT) in intermediate to advanced hepatocellular carcinoma (HCC) patients.
Methods |
Data from 168 intermediate to advanced HCC patients who received TACE alone (N = 49) or TACE plus ACT (N = 119) were extracted. Besides, ACT was defined as apatinib with or without other therapy, such as arsenic trioxide, microwave ablation and radioactive seed implantation.
Results |
In TACE plus ACT group, the median overall survival (OS) was 30 months (95% confidence interval (CI): 24–40 months) with 1-year, 3-year and 5-year OS rate of 84.0%, 41.2% and 21.5%, respectively. While in TACE group, the median OS was only 14 months (95%CI: 11–17 months) with 1-year, 3-year and 5-year OS rate of 55.1%, 18.4% and 16.1%, separately. By comparation, the OS was prolonged in TACE plus ACT group compared with TACE group (P<0.001). After adjusted by multivariate Cox's regression analysis, TACE plus ACT (vs. TACE) independently related to the longer OS (hazard ratio: 0.504, P = 0.001). In TACE plus ACT group, the most frequent adverse events included hand-foot syndrome (95.8%), hypertension (95.8%), fatigue (90.8%), albuminuria (85.7%), anorexia (79.0%), diarrhea (66.4%), myelosuppression (58.8%), nausea/vomiting (49.6%) and abdominal pain (39.5%), besides, no grade 4 adverse events and treatment-related death occurred.
Conclusion |
TACE plus ACT is a promising treatment choice for the intermediate to advanced HCC patients.
Le texte complet de cet article est disponible en PDF.Keywords : Apatinib, Transarterial chemoembolization, Multimodal therapy, Hepatocellular carcinoma, Survival
Abbreviations : HCC, TACE, PFS, VEGFR-2, AS2O3, MWA, ACT, PS, PVTT, BCLC, SD, CI, HR
Plan
Vol 46 - N° 6
Article 101869- juin 2022 Retour au numéro
Article précédent
- SIB-IMRT combined with apatinib for unresectable hepatocellular carcinoma in patients with poor response to transarterial chemoembolization
- Xuefen Liu, Jiangping Luo, Longbin Zhang, Fan Yang, Dong Peng
- Partial splenectomy in children undergoing liver transplantation or venous shunt for severe hypersplenism: A case control comparative study
- Olivier Boillot, Sophie Chopinet, Emilie Gregoire, Laurent Milot, Philippe Petit, Barbara Rohmer, Bertrand Roquelaure, Anne Dariel, Nicoleta Panait, Jean Hardwigsen, Jérôme Dumortier
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?